A Clinical Observation Study of Vancomycin Therapeutic Drug Monitoring in Gram Positive Bacteria Infected Patients

Conditions

Gram Positive Bacteria Infection

Liping Wang, Qing Yuan, Min Tan, Shuanshuan Xie, Jufang Wu et al. (7 authors)

Experimental and Therapeutic Medicine2019-01-2113 citations

10.3892/etm.2019.7188

A Prospective Multicenter Clinical Observational Study on Vancomycin Efficiency and Safety With Therapeutic Drug Monitoring

Xiaoyu Liang, Yaxing Fan, Minjie Yang, Jing Zhang, Jufang Wu et al. (30 authors)

Clinical Infectious Diseases2018-08-1043 citations

10.1093/cid/ciy680

[Monitoring of vancomycin serum concentrations and the evaluation of its safety and treatment outcomes in adult patients].

Huifang Zhang, Ruilan Wang, Wen Shu, Rong Tang, Xiaoyu Liang et al. (7 authors)

PubMed2018-06-012 citations

10.3760/cma.j.issn.2095-4352.2018.06.007

Interventions

Vancomycin Therapeutic Drug Monitorin:Vancomycin Therapeutic Drug Monitorin

Eligibility

Sex/Gender

All

Age

No minimum to 100 Years

Inclusion criteria

Inclusion criteria: 1. Patients should have clinical symptoms, signs, laboratory examinations to be diagnosed as gram positive bacteria infections, which met the indication of vancomycin therapy; 2. Patients had to have an expected survival of >=5 days.

Exclusion criteria

Exclusion criteria: 1. Patients with treatment with linezolid or teicoplanin for 24 hours within or before the 72-hour prestudy period were excluded; 2. All patients who were considered to have MRSA colonization were excluded; 3. Patients failed to receive TDM were excluded; 4. Pregnant or lactating women were excluded; 5. Patients with treatment with aminoglycoside were excluded.

Design outcomes

Primary

Measure	Time frame
Serum vancomycin concentration;	—

Countries

China

Contacts

Public ContactJing Zhang

zhangj61@fudan.edu.cn+86 13816357098

Outcome results

None listed